Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 oct. 2024 20h18 HE | Source: Robbins LLP

SAGE REMINDER – Robbins LLP Urges SAGE Investors to Obtain Legal Counsel in Light of the Pending Lead Plaintiff Deadline

Robbins LLP is Investigating Allegations that Sage Therapeutics, Inc. (SAGE) Misled Investors Regarding the Efficacy of its New Drugs
17 sept. 2024 19h45 HE | Source: Robbins LLP

SAGE CLASS ACTION: Sage Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit

Robbins LLP is Investigating Allegations that Sage Therapeutics, Inc. (SAGE) Misled Investors Regarding the Efficacy of its New Drugs
04 sept. 2024 18h25 HE | Source: Robbins LLP

SAGE Class Action Alert: Robbins LLP Reminds Stockholders of the Sage Therapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Sage Therapeutics, Inc. (SAGE) Misled Investors Regarding the Efficacy of its New Drugs
29 août 2024 15h37 HE | Source: Robbins LLP

Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Sage Therapeutics, Inc.

Robbins LLP is Investigating Allegations that Sage Therapeutics, Inc. (SAGE) Misled Investors Regarding the Efficacy of its New Drugs